LABRAD : Vol 44, Issue 2 - September 2018 by Aga Khan University Hospital, Karachi
eCommons@AKU 
LABRAD Publications 
9-2018 
LABRAD : Vol 44, Issue 2 - September 2018 
Aga Khan University Hospital, Karachi 
Follow this and additional works at: https://ecommons.aku.edu/labrad 
 Part of the Pathology Commons, and the Radiology Commons 
Newsletter of tHe DepartmeNts of patHology & laBoratory meDICINe aND raDIology
septemBer 2018 Vol. 44, IssUe 2
Faecal
Calprotectin
Calprotectin ≤50
µg/g
Likely functional
gastrointestinal
disorders
Calprotectin ≥120
µg/g
Active
inflammation in
the GI system
Further diagnostic
testing is required
Calprotectin 50-120
µg/g
Mild inflammatory
process: treated IBD
or infection,
NSAIDS/Asprin/PPI
use
Retesting in 6 to 6
weeks
Calprotectin ≤50
µg/g
noninflammatory
condition
Calprotectin >50
µg/g
suggest
colonoscopy
2VOL. 44, ISSUE 1SEPTEMBER 2018
A Publication of the Departments of Pathology & Laboratory Medicine and Radiology
Inappropriate Requesting Of Glycated Haemoglobin  3
(HBA1c) By Clinicians 
Fecal Pancreatic Elastase: A Test for Pancreatic Insufficiency 6
Radiology Pathology Correlation 11
Myelodysplastic Syndromes (MDS) 12
Aplastic Anemia 19
Fecal Calprotectin (S100a8/S100a9) 5
Megaloblastic  Anemia 18
WHO Classification of Head and Neck Tumours: An Update 14
Plasma Metanephrines in Diagnosis of Pheochromocytoma      16
Transfusion Associated Circulatory Overload (Taco):  20
A Severe But Preventable Transfusion Reaction
September 2018
Volume 44, Issue 2
Editor
Dr Natasha Ali
Associate Editor
Dr Lena Jafri
Editorial Committee
Department of Pathology and Laboratory 
Medicine
Dr Nasir Ud Din
Dr Joveria Farooqi
Dr Zahra Hasan
Dr Anila Rashid
Radiology
Dr Naila Nadeem
Dr Dawar Khan
Labrad Administration Office
Farhana Arshad
Department of Pathology and 
Laboratory Medicine
Aga Khan University Hospital
Stadium Road, P. O. Box 3500
Karachi 74800, Pakistan
Tel: 92 21 3486 1551
Fax: 92 21 3493 4294, 3493 2095
hospitals.aku.edu/Karachi/clinical-laboratories
3VOL. 44, ISSUE 1SEPTEMBER 2018
The second issue of 2018 is non-thematic. Apart 
from sharing knowledge on glycated haemoglobin, 
fecal calprotectin, Factor V clotting assay and 
aplastic anaemia, we have also included a short 
review of TNM classification of head and neck 
cancers along with an article on radiology pathology 
correlation. The contributing authors have written 
an update on transfusion associated circulatory 
overload with quick pointers on how to diagnose the 
condition.
It is hoped that this issue will further enhance 
the awareness and education of our physicians in 
diagnosing common and rare medical conditions
Natasha Ali
From the Editor’s Desk
Inappropriate Requesting Of Glycated 
Haemoglobin (HBA1c) By Clinicians
Dr Faryal Husnain
Chemical Pathology
Seventy percent of patients’ management related 
decisions are based on Laboratory testing but there 
are no checks in place to measure appropriateness 
of test ordering in our present clinical setup. 
There exist a major quality gap, which leads to 
clinicians ordering inappropriate tests or tests that 
don’t necessarily help the patients’ diagnoses or 
treatment plans. The HbA1c testing is one of its 
example. This article will explain the appropriate and 
inappropriate utilization of the HBA1c testing in the 
light of latest international guidelines by American 
Diabetic Association (ADA) so that our resources 
can be better utilized to serve our patients and avoid 
unnecessary tests.
The HBA1c is a glycated variant of Hemoglobin-A 
resulting from non-enzymatic attachment of various 
carbohydrates to valine in N-terminal of the beta-
chain of Haemoglobin, which exists under normal 
physiological conditions. Glucose can attach to 
other sites as well but HBA1c is the most abundant 
glycated species. Since the protein is located inside 
the erythrocytes, glycation is related to the lifespan 
of erythrocytes. HbA1c provides an estimate of mean 
blood glucose over the lifespan of the erythrocyte 
(3–4 months). 
This variant increases considerably in concentration 
in patients with uncontrolled blood glucose levels 
and is used to diagnose and monitor glycemic control 
in Diabetes Mellitus and to predict the development 
of microvascular complications in Diabetic patients. 
HbA1c testing became commercially available 
in the 1970s, but the clinical utility of HbA1c did 
not become obvious until 1993 when the Diabetes 
Control and Complications Trial (DCCT) was 
published. This trial proved the association between 
HbA1c and diabetes complications and resulted in 
specific treatment goals for people with diabetes.
Based on the DCCT, the ADA recommended 
routine measurement of HbA1c with specific 
targets to monitor glycemic control in diabetics. 
The National Glycohemoglobin Standardization 
Program (NGSP) was initiated in 1996 with the 
goal of standardizing reported results to the to the 
DCCT reference, regardless of the glycated species 
measured, which resulted in a lot of improvement in 
the comparability of results. This was followed by 
World Health Organization (WHO), recommending 
HbA1c as a criterion for the diagnosis of Diabetes 
Mellitus in 2011.
Factors Causing Variation in HBA1c Results
The HBA1c can give skewed results in people 
with certain conditions, such as hemolytic or other 
anemia’s, sickle cell disease, use of drugs that 
stimulate erythropoiesis, recent blood transfusion, 
end-stage kidney disease, in people with hemoglobin 
variants (HbS, HbF or HbG). Other factors that 
can cause falsely elevated results are, uremia 
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adequate for monitoring a particular patient’s 
glycemic control or when using A1C as the sole 
basis for assessing glycemic control, particularly 
if the result is close to medical decision level 
thresholds. Patients should be assessed for the 
factors that can affect HbA1c results, especially 
in our population where certain aforementioned 
conditions are common. In such cases glycemic 
control is best evaluated by the combination of 
results from HbA1c and serial or continuous 
blood glucose monitoring using a point of care 
device.
(BUN>85mg/dl), hypertriglyceridemia (>1,750mg/
dl), chronic alcohol consumption, high bilirubinemia 
(>20mg/dl), chronic aspirin use and pregnancy 
(2nd and 3rd trimester). According to the ADA 
recommendations, HBA1C must be forgone if there 
is disagreement between A1C and blood glucose 
levels. In such cases, the clinician may consider 
alternate diagnostic tests such as fasting plasma 
glucose test or oral glucose tolerance test.
Thereby Clinicians need to be aware of these 
limitations and assess whether HBA1c is 
determining whether or not a patient has immune 
hemolytic anemia is 83% in a patient with hemolytic 
anemia but only 1.4 percent in a patient without 
hemolytic anemia. So, before interpreting DAT the 
clinical and laboratory evidence of haemolysis needs 
to be established. 
Direct antiglobulin test is valuable in diagnosis 
of: (a) autoimmune hemolytic anaemia; (b) drug-
induced immune haemolytic anaemia; (c) haemolytic 
transfusion reactions due to alloantibodies; and (d) 
hemolytic disease of the fetus and newborn.
Indirect antiglobulin test is useful for: (a) detection 
of antibodies in serum, i.e., antibody screening & 
identification, and crossmatching; (b) detection of 
antibodies in eluates prepared from sensitized RBCs; 
and (c) typing of RBCs when testing for weak D 
phenotypes.
Antiglobulin test was first described in 1940s by 
Coombs et al. and Boorman et al. to identify the 
immune mediated nature of haemolysis. It simply 
enhances the antibodies bound to the surface of red 
blood cells that would not agglutinate on its own. 
With the help of antihuman globulin or antiserum, 
i.e., Coombs reagent, those sensitized red blood 
cells agglutinate and, thus, verifying the immune-
mediated haemolysis. 
Alternatively it is used for the identification of 
antibodies by reacting a patient’s serum with red 
cells of known antigenic signature. The former 
method is known as ‘Direct (Coombs’) antiglobulin 
test or DAT’ (2, 3) while the latter, which is more 
commonly used, is known as ‘Indirect (Coombs’) 
antiglobulin test or IAT’ (1).  It is a quick, cheap and 
inexpensive test producing very useful information. 
However, the predictive value of a positive DAT for 
Antiglobulin Test
Dr Ruhul Quddus
Haematology & Transfusion Medicine
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Calprotectin is a marker to diagnose or monitor 
IBD, presently considered a gold standard, 
included in clinical practice guidelines and its 
levels correlate with the severity of IBD. Increased 
levels of fecal calprotectin may be helpful in 
distinguishing Inflammatory Bowel Disease (IBD) 
from functional gastrointestinal disorders, such as 
irritable bowel syndrome (IBS). Calprotectin is 
observed to perform better in predicting ulcerative 
colitis then Chron’s disease. Fecal calprotectin has 
sensitivity and specificity both of approximately 
85 percent, for this differential diagnosis. Meta-
analysis have reported that calprotectin perform 
better in adults (sensitivity 93 percent & specificity 
96 percent) than children (sensitivity 92 percent 
& specificity 76 percent). However, it must be 
kept in mind that elevated concentrations of fecal 
calprotectin are not diagnostic for IBD, as other 
disorders such as colorectal cancer, gastrointestinal 
infections and celiac disease may also be associated 
with neutrophilic inflammation. 
Calprotectin, is a member of the S100 calcium-
binding protein family, formed as a heterodimer 
of S100A8 and S100A9. It is expressed mainly by 
granulocytes and, to a lesser extent, by epithelial 
cells and macrophages/monocytes. In neutrophils, 
approximately 60 percent of the total cytoplasmic 
protein content is made up of calprotectin. 
Activation of the intestinal immune system results 
in recruitment of neutrophils. Cellular proteins, 
including calprotectin are released from these 
neutrophils after their activation. These proteins limit 
the growth of bacteria and fungi by sequestering 
manganese and zinc.
Eventually calprotectin enters the lumen of the gut 
after translocation across the epithelial barrier. With 
the progress of inflammatory process, the fecal 
material absorbs the released calprotectin before it is 
excretion from the body. The amount of calprotectin 
present in the feces is proportional to the number 
of neutrophils within the gastrointestinal mucosa 
and can be used as an indirect marker of intestinal 
inflammation.
Fecal Calprotectin (S100a8/S100a9)
Dr Siraj Munir
Chemical Pathology 
Figure 1: Algorithmic approach to a patient suspected with Inflammatory Bowel Disease (Adapted from: Faecal markers of gastrointestinal inflammation. 
July 2012Journal of clinical pathology 65(11):981-5. DOI: 10.1136/jclinpath-2012-200901)
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Table 1: Clinical utility, Limitations, clinical sensitivity and specificity of 
Fecal Calprotectin use.
Fecal Pancreatic Elastase: A Test for 
Pancreatic Insufficiency
Elastase is an enzyme produced by exocrine 
tissue in the pancreas. The pancreas is an organ 
located in the abdomen that consists of two kinds 
of tissues: exocrine and endocrine. The exocrine 
pancreas is responsible for producing elastase 
along with other enzymes that are transported to 
the small intestine to break down fats, proteins, 
and carbohydrates as part of food digestion. This 
test measures the amount of elastase in stool 
(feces) to evaluate whether a person’s pancreas is 
functioning properly.
Exocrine pancreatic insufficiency (PEI) causes 
problems in food digestion, as the body is 
unable to break down and absorb nutrients in the 
absence of enzymes. When you have PEI, you 
might lose weight or have pain in your abdomen 
and can experience symptoms associated with 
malabsorption and, in severe cases, symptoms of 
malnutrition which can in turn lead to anemia, 
rickets or osteomalacia.
Fecal elastase is an enzymatic product of 
pancreatic secretion that remains relatively stable 
during transport through the gastrointestinal 
tract. The fecal elastase-1 reflects the secretory 
capacity of the pancreas. The elastase test 
is usually done when a person has signs and 
symptoms of pancreatic insufficiency e.g. 
abdominal cramps, bloating, foul-smelling, 
bulky or greasy stools, in children; inability 
to gain weight, delayed growth, malnutrition, 
vitamin deficiencies and weight loss. The test 
is also used in assessing exocrine pancreatic 
function in cystic fibrosis, diabetes mellitus, or 
chronic pancreatitis. Fecal Elastase at Aga Khan 
clinical laboratories is done by Enzyme linked 
immunosorbent assay (ELISA) and decreased 
amount indicates that the person has pancreatic 
insufficiency. The stool sample should be formed 
(not watery) and not contaminated with urine or 
water. The test may show false low results if the 
sample of stool is watery, such as with diarrhea 
as the water in the stool will dilute the elastase 
and decrease the amount measured. If patient 
is taking pancreatic enzymes, they should be 
discontinued for five days before taking stool 
sample.
Fecal Elastase test is a reliable test for the 
assessing pancreatic function in many pancreatic 
and non-pancreatic diseases. It is non-invasive, 
give results in short duration, and is not affected 
by pancreatic enzyme replacement therapy. It is a 
useful test for screening of patients who may be 
at risk of pancreatic dysfunction.
Dr Tayyaba Hassan
Chemical Pathology
Calprotectin is resistant to bacterial degradation 
in the gut and is stable in stool for up to one 
week at room temperature and is readily 
measured using immunochemical techniques. 
Limitations and diagnostic accuracies are 
conversed in table1.
Indication
Distinguishing functional from 
organic bowel disease and 
predicting relapse in IBD
Limitations
• Disease nonspecific
• Affected by age, comorbidities, NSAIDs use
• Day to day variations 
• Miss low level inflammatory activity
Sensitivity
70-100%
Specificity
70-100%
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Factor V Clotting Factor Assay Instead of Factor 
V Leiden Assay (Activated Protein C Resistance) 
As A Part of Thrombophilia Screening; 
A Misconception to be Re-Conceptualized
Factor V Leiden ((FVL)) is a mutant coagulation 
factor V. The FVL mutation causes insensitivity 
of factor V (both the activated and inactive forms) 
to the actions of activated protein C (aPC), a 
natural anticoagulant. As a result, individuals who 
inherit the FVL mutation have high risk of venous 
thromboembolism. FV Leiden-induced APC 
resistance accounts for 20 percent of unselected 
patients with first-episode thrombosis, 50 
percent of familial thrombosis, and 60 percent of 
thrombotic patients known to have normal levels 
of protein S, protein C, anti-thrombin, and anti-
phospholipid antibodies.
Dr. Farrukh Zia
Clinical Haematology
 Fecal elastase < 50
High probability of PEI Yes No Low probability of PEI
Fecal elastase < 200
and normal
nutritional panel
Clinical suspicion
of PEI
Evaluation of serum
nutritional markers
and fecal elastase
Fecal elastase 15-200
or > 15 with
abnormal nutritional
markers
MPD dilatation or
calcifications on imaging?
Figure 1: Diagnostic approach of suspected pancreatic exocrine insufficiency (Source: Lindkvist B. Diagnosis and treatment of pancreatic exocrine 
insufficiency. World J Gastroenterol 2013; 19(42): 7258-7266)
Figure 1: Mechanism of Action of Activated protein C, rendering inacti-
vation of Factor V 
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Circumstantial risk factors for VTE in Leiden variant 
heterozygotes or homozygotes are summarized in 
following table 1,
A Short Review of the Major Changes in the 
TNM Classification of Head and Neck Cancers 
in The American Joint Committee on Cancer 
Eighth Edition of Cancer Staging Manual
Dr Sabeehuddin Siddique
Histopathology
Introduction
Cancer staging is an important component of patient 
care across the world. The primary purpose of TNM 
system is to provide an anatomic-based classification 
Rodger et al 2010 evaluated in a study of prospective 
cohort that there is a slightly increased risk of 
pregnancy loss in women with the Leiden variant 
(4.2 percent) compared to those without the variant 
(3.2 percent) (odds ratio 1.52).
Scenario in Pakistan
In Pakistan, thrombo-embolic events due to inherited 
or acquired thrombophilias are not very uncommon. 
In a study conducted by Nadir et al in Rawalpindi, 
overall FVL mutation was observed in 14.5 percent 
patients of thrombophilia. It was detected in five 
to adequately depict cancer prognosis and treatment 
outcome. To maintain clinical relevance, AJCC 
(American Joint Committee on Cancer) periodically 
revises and updates the TNM Classification. The 
latest (8th) edition of AJCC Cancer staging manual 
percent patients of CVA, nine percent in PE, 33 
percent in DVT and 17 percent in PV patients. In 
another study conducted by Khalid et al at AKUH,  
FVL mutation was detected in 14.2 percent patients 
suffering thromboembolism.
Discussion
There is a common misconception in our health 
professionals while screening the patients for 
thrombophilias that they advise Factor V clotting 
factors assay instead of Factor V Leiden (Activated 
protein resistance) which results in wastage of 
resources as well as cost burden over the patients. It 
also causes delay in the patient diagnosis and proper 
management.
In the month of July 2018 in Aga khan Hospital, 
Karachi total of 476 samples were received for 
thrombophilia screening including Protein S, Protein 
C, Antithrombin III and Homocysteine levels. The 
request for Factor V Leiden was found in 74 samples 
while 17 samples were mistakenly labelled for Factor 
V clotting factor Assay.
Hence, there is a need to develop awareness and 
educate our health professionals regarding this 
important issue in order to solve the problem. 
Efforts can be made collectively through on line 
interactive sessions, publications, conducting 
CME’s, distribution and availability of education 
material and brochures on collection point of labs, 
clinics and hospitals.       
Circumstance
Malignancy 
Central venous catheter use
Travel
Minor leg injury
Age
Oral HRT 
Obesity (BMI >30 kg/m2)
Relative Risk for VTE
Unknown: probably modest
2x-3x ↑ relative risk
5x ↑ relative risk in those 
w/cancer
2x ↑ relative risk
8x ↑ relative risk when traveling 
≥4 uninterrupted hours
23x-50x ↑ risk
After age 45 years lifetime risk = 
17% (vs 8% in general 
population)
7x-25x ↑ relative risk
5x-12x ↑ relative risk
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Head and Neck Carcinoma of Unknown Primary 
and Modification of N Categories (inclusion of 
the extranodal extension): An independent chapter 
describing the principles of Carcinoma of Unknown 
Primary (CUP) in head and neck has been introduced 
in the AJCC Staging Manual. T0 will be assigned for 
all CUPs for EBV-positive CUP and HPV-positive 
CUP, the N classification follows nasopharyngeal 
carcinoma and HPV-positive OPC definitions 
respectively and requires biological assessments 
to direct their assignations. For the remainder 
N classification is instituted by inclusion of the 
extranodal extension variable. Since its presence has 
been shown to have independent adverse prognostic 
impact for non-viral related head and neck carcinoma 
(Table 3).
Notably, inclusion of extranodal extension is 
included in both clinical and pathological staging, 
carries some major changes in the criteria of head 
and neck cancer staging and the most important ones 
are discussed here.
New TNM Classifications
HPV-mediated (p16+) Oropharyngeal 
Carcinoma (OPC) : In response to an urgent need 
to properly depict the character and prognosis 
of this recently described disease, a new staging 
system has been introduced for HPV-positive OPC 
in the 8th edition TNM (Table 1). It is also for the 
first time that separate clinical and pathological 
N-definitions and T-N groupings have been 
introduced in the HNC classification. The clinical 
staging system has been based on the proposal of 
the International Collaboration on Oropharyngeal 
cancer Network group.  
Head and Neck Soft Tissue Sarcoma (HN-
STS): It is another new classification introduced 
in the 8th edition TNM. In the previous edition 
HN-STS used the same TNM classification as 
soft tissue sarcomas of other sites. Although 
they are biologically similar, HN-STS present 
some unique characteristics. The traditional 
5-cm size cut-point separating T1 and T2 soft 
tissue sarcomas of the extremity and trunk lacks 
relevance for HN-STS since the majority of 
patients in recent studies do not even reach the 
5 cm cut-off. In this edition, the 2 cm and 4 cm 
breakpoint for T category was arbitrarily chosen 
based on traditional HNC size criteria; T1 ≤2 
cm, T2 >2 to ≤4c cm, and T4 for very extensive 
tumours (Table 2).
Table 1. The 8th edition clinical and pathologic TNM 
classification for the HPV-mediated oropharyangeal cancer
Table 2. Definition of the T category in the 8th edition TNM for cancer of 
oral cavity, soft tissue sarcoma of the head and neck cutaneous 
carcinoma of the head and neck
Table 3. The 8th edition N classification for non-viral related head and 
neck cancer and stage grouping for viral and non-viral unknown primary 
- cervical nodes
(Adapted from Shao H Huang and Brian O’ Sullivan. Overview of the 8th 
edition TNM classification for head and neck cancer. Curr Treat Options 
in Oncol. (2017) 18: 40)
(Adapted Shao H Huang and Brian O’ Sullivan. Overview of the 8th 
edition TNM classification for head and neck cancer. Curr Treat Options 
in Oncol. (2017) 18: 40)
(Adapted from Shao H Huang and Brian O’ Sullivan. Overview of the 8th 
edition TNM classification for head and neck cancer. Curr Treat Options 
in Oncol. (2017) 18: 40)
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not only for CUP but also for all non-viral related 
head and neck carcinomas, including salivary gland 
malignancies, with the exception of melanoma, soft 
tissue sarcomas, and thyroid cancer. Since several 
studies have shown that CT or MRI cannot reliably 
determine the presence of extranodal extension, 
therefore the criteria of clinical extranodal extension 
is however different from that of the pathological 
one and only refers to those unambiguous clinical/ 
radiological evidence of gross extranodal extension, 
such as dermal involvement or soft tissue invasion 
with deep tethering to underlying muscle, adjacent 
structures or clinical signs of nerve involvement. 
From pathologic perspective, soft tissue deposits in 
the lymphatic drainage pathways without identifiable 
lymph node(s) would be recorded as positive LN 
with positive extranodal extension because it would 
represent a LN totally replaced by metastatic deposit.
MODIFICATION OF ‘T’ AND ‘N’ 
CATEGORIES
Nasopharyngeal carcinoma--modification of the 
T and N categories:  In comparison to the previous 
edition of the AJCC Manual, notable changes have 
been introduced to the ‘T’ and ‘N’ categories of 
nasopharyngeal carcinoma in the 8th edition of 
AJCC Manual (Table 4). The These changes have
resulted from more accurate imaging permitting 
better delineation of tumour extent and early 
detection of occult metastases linked to advances in 
radiotherapy with increasing conformity of tumour 
coverage and sparing of uninvolved structures and by 
the contemporary use of combination chemotherapy 
that improves tumour control and cure rates, 
especially for advanced loco-regional disease. Two 
prognostic factors that were previously listed under 
the nasopharyngeal carcinoma staging and which 
have been eliminated from the 8th edition of AJCC 
Manual are pre-treatment plasma EBV-DNA copy 
number and gross tumour volume. The EBV-DNA 
copy number has been omitted due to the challenges 
arising from the feasibility and practicality of the test 
and also because of lack of standardization of testing 
methods between laboratories. The Gross tumour 
volume has been deleted due to the paucity of data 
on the reliability and practicality in deriving this 
parameter by radiologists. 
Oral squamous cell carcinoma—modification of 
the T categories (inclusion of depth of invasion): 
Depth of invasion (DOI) or tumour thickness is 
another dimension of tumour size that likely reflects 
the proximity to underlying lymph-vascular structures. 
It has been reported as a good predictor of the 
presence of pathologic overt LNs. The definition 
of ‘T’ categories for oral cavity cancers using cut-
offs of 0.5 and 1.0 cm for T1, T2 and T3 tumours, 
respectively, according to the following criteria T1: ≤2 
cm in maximum size and ≤0.5 cm in DOI; T2: ≤2 cm 
in maximum size with DOI between 0.5–1.0 cm, or 
2–4 cm sized lesion and DOI ≤1.0 cm; and T3: >4 cm 
in size or any tumour with DOI >1.0 cm (Table 2).
Head and neck cutaneous carcinoma—
modification of T category (reintroduction of 
tumour size criteria): In the non-merkel cell 
cutaneous carcinoma of the head and neck chapter 
of the 8th edition of AJCC Manual, size criteria 
were reintroduced for ‘T’ classification because 
many studies have shown  a strong correlation 
between the tumour size and more biologically 
aggressive behavior of disease. The cut-off point for 
primary size is now in line with other mucosal head 
and neck squamous cell carcinomas where a ≤ 2 cm 
primary is classified as T1 and a 2–4 cm primary 
is classified as T2, a larger tumour (>4 cm) or with 
other high-risk features is classified as T3 (DOI 
> 0.6 cm or peri-neural invasion or minor bone 
erosion) or T4 (major invasion of bone or skull 
base).
Table 4. Change  of the T and N categories in the 8th edition compared to 
7th edition TNM classification for nasopharyangeal cancer
(Adapted from Shao H Huang and Brian O’ Sullivan. Overview of the 8th 
edition TNM classification for head and neck cancer. Curr Treat Options 
in Oncol. (2017) 18: 40)
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A 21 year old male presented with left shoulder 
pain. X-ray was obtained which showed focal lesion 
having popcorn type of calcification in left humeral 
proximal end.
The tumour was curetted and histological 
examination showed circumscribed lobules of 
hypocellular hyaline cartilage with peripheral 
rim of reactive bone. No binucleation, mitosis or 
host bone entrapment was seen. Final diagnosis 
was Enchondroma after radiological-pathological 
correlation.
Radiology Pathology Correlation
Dr Nasir Ud Din and Dawar Khan
Histopathology and Radiology 
Enchondromas are relatively common benign cartilage 
tumours. Majority of patients present within two 
to five decades of life. Tumour most commonly 
involves small tubular bones of hand (approx. 40 
percent). In long bones, proximal humerus, distal tibia, 
proximal and distal femur is commonly involved. 
Clinical presentation is swelling with or without pain.  
Radiologically, enchondromas are benign mostly 
medullary lytic lesion in long bones with rings, arcs 
and popcorn type of calcification. Usually it has no 
periosteal reaction or no soft tissue mass. 
Radiological differential diagnosis in long bones is bone 
infarct. Bone infarcts tend to have a well-circumscribed, 
sclerotic margin. Calcification in bone infarct is 
geographical in appearance and denser. Histologically, 
increase cellularity and binucleation is seen in tumours 
of digits and those occurring in syndromes which may 
cause confusion with chondrosarcoma. However, host 
bone permeation is not seen.
Almost 90 percent of enchondromas are solitary. 
Multiple lesions occur in syndromes: Ollier disease, 
Maffucci syndrome and metachondromatosis. 
Malignant transformation of isolated lesion into 
chondrosarcoma is very rare. Increased incidence of 
malignant transformation is seen in enchondromatosis. 
Local recurrence following curettage is uncommon 
(three-four percent). Local recurrence should raise 
suspicion of chondrosarcoma.
Figure 1: Anteroposterior view shows well defined focal lesion with 
popcorn type of calcification in left humeral proximal end.         
Figure 2A,B: Low and high power shows lobules of hyaline cartilage.         
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The myelodysplastic syndromes (MDS) comprise 
a heterogeneous group of malignant hematopoietic 
stem cell disorders characterized by dysplastic 
(figure1) and ineffective blood cell production. MDS 
occur most commonly in older adults and may occur 
de novo or arise years after exposure to potentially 
mutagenic therapy (eg, radiation exposure, 
chemotherapy).
The diagnosis of MDS should be considered in 
any patient with unexplained cytopenia(s) or 
monocytosis. Careful inspection of the peripheral 
Myelodysplastic Syndromes (MDS)
Dr Qayyum Khan & Dr Anila Rashid
Hematology & Transfusion Medicine
blood smear and bone marrow aspirate is necessary 
to document the requisite dysplastic cytologic 
features identifiable in any or all of the hematopoietic 
lineages [table 1].
Bone marrow aspirate provides material for a 500-
cell differential count to determine the percentage 
of blasts in the marrow; it also allows for a detailed 
cytologic evaluation of the blasts and other cells. 
Impaired myeloid maturation is often readily 
apparent. The percentage of granulocytic precursors 
is variable, but more often decreased than increased, 
and a relative maturation arrest may be seen at the 
myelocyte stage. Maturation of the cytoplasm may 
progress more rapidly than the nucleus.
The bone marrow biopsy gives a general overview 
of the degree of involvement and specific histologic 
features associated with the process.
Detection of certain chromosomal abnormalities by 
routine cytogenetic analysis, reverse transcriptase 
polymerase chain reaction (RT-PCR), or fluorescent 
in situ hybridization (FISH) distinguishes between 
MDS and acute myeloid leukemia (AML) in some 
cases, aids in the classification of MDS, and is a 
major factor in determining prognostic risk group 
and therapy.
Figure 1: Decreased nuclear lobes in myelodysplasia (pseudo Pelger-Huet 
anomaly)
 Table 1: Morphologic abnormalities in myelodysplastic syndrome
Lineage
Erythroid
Myeloid
Megakaryocytes
Peripheral Blood
Anisocytosis
Poikilocytosis
Basophilic stippling
Nucleated red cells
Tear drop cells
Granulocyte nuclear hypolobation 
(pseudo PelgerHüet) 
Granulocyte cytoplasmic 
hypo/degranulation Blasts
Platelet anisocytosis 
Giant platelets
Bone Marrow
Nuclear budding 
Internuclear bridging 
Karyorrhexis 
Multinuclearity
Nuclear hyperlobation
Megaloblastic changes
Ring sideroblasts 
Nuclear hypolobation (pseudo Pelger-Hüet) 
Irregular hypersegmentation Bizarre nuclear shapes 
Decreased granules; agranularity 
Pseudo Chediak-Higashi granules 
Auer rods
Micromegakaryocytes 
Nuclear hypolobation 
Dispersed nuclei 
Degranulation
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The presence of one of the following chromosomal 
abnormalities is presumptive evidence of MDS 
in patients with otherwise unexplained refractory 
cytopenia and no morphologic evidence of dysplasia.
The presence of one of the following chromosomal 
abnormalities is presumptive evidence of MDS 
in patients with otherwise unexplained refractory 
cytopenia and no morphologic evidence of dysplasia.
●-7/del(7q)
●-5/del(5q)
●del(13q)
●del(11q)                                                                                                     
●inv(3)(q21q26.2)
Myelodysplastic Syndrome Subtypes: WHO 2016
The WHO classification system distinguishes 
six general entities with the following estimated 
percentages
MDS with single lineage 
dysplasia
MDS with multilineage 
dysplasia
MDS with ring 
sideroblasts (MDS-RS)
MDS-RS with single
lineage dysplasia 
MDS-RS with 
multilineage dysplasia 
MDS with isolated del(5q) 
MDS with excess blasts
(MDS-EB)
MDS-EB-1 
MDS-EB-2 
MDS, unclassifiable 
(MDS-U)
-with 1% blood blasts 
-  with single lineage dys-
plasia and pancytopenia
-based on defining 
cytogenetic abnormality
Refractory cytopenia of 
childhood 
1
2 or 3 
1
2 or 3 
1-3 
0-3 
0-3 
1-3
 
1 
0 
1-3 
1 or 2
1-3 
1 or 2
1-3 
1-2 
1-3 
1-3 
1-3 
3 
1-3 ,
1-3 
<15% / <5% (If SF3B1 mutation is 
present)
15%/, <5% (If SF3B1 mutation is present)
≥15% / ≥5 (If SF3B1 mutation is present)
≥15% / ≥5%(If SF3B1 mutation is 
present)
None or any 
None or any  
None or any 
None or any
None or any 
15%
None 
BM < 5%, PB < 1%, no 
Auer rods
BM <5%, PB <1%,
no Auer rods
BM < 5%, PB < 1%,
no Auer rods
BM <5%, PB < 1%, 
no Auer rods
BM < 5%, PB < 1%, 
no Auer rods
BM 5%-9% or PB 2%-4%,
 no Auer rods
BM 10%-19% or PB 5%-
19%
or Auer rods
BM <5%, PB =1%,
no Auer rods
BM <5%, PB <1%, 
no Auer rods
BM <5%, PB <1%,
no Auer rods
BM <5%, PB <2%
Name
Dysplastic 
Lineage Cytopenias 
Ring Sideroblasts as % of
Marrow Erythroid Elements 
Bone Marrow (BM) 
Peripheral Blood (PB) 
Blasts
Differential Diagnosis of MDS
MDS must be distinguished from other entities that 
may also present with cytopenias and/or dysplasia. 
The following are the most common entities that 
should be considered.
1. Idiopathic cytopenia of undetermined significance 
2. Acute myeloid leukemia 
3. MDS/MPN syndromes
4. Aplastic anemia
14
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WHO Classification of Head and Neck 
Tumours: An Update
Introduction
The recent 4th edition of World Health 
Organization (WHO) classification of head and 
neck tumours (the so called “blue book”) was 
published in 2017 after a decade. In this edition, 
a number of significant changes made across 
all tumour sites including introduction of new 
entities. This paper summarizes important changes 
in head and neck tumours.
Salivary Glands
Mammary analogue Secretory carcinoma 
(MASC) was first described by Sakalova et al in 
2010. This tumour was introduced in recent blue 
book, but renamed it as “Secretory carcinoma”. 
It has morphological and immunohistochemical 
similarity to secretory carcinoma of breast. In the 
past, this tumour was being diagnosed as “zymogen-
poor acinic cell carcinoma”, low grade cribriform 
cystadenocarcinoma and adenocarcinoma, NOS. 
Most cases occur in parotid gland, but have 
been reported in minor salivary glands as well. 
Histologically, microcysts containing eosinophilic 
secretions are characteristic. Tumour cells express 
CK7, S-100 protein, and mammaglobin and harbours 
t(12;15)(p13;q25) translocation resulting in ETV6-
NTRK3 fusion.
Polymorphous low grade adenocarcinoma has 
been renamed as polymorphous adenocarcinoma 
(PAC). The term low grade was omitted due to 
aggressive behavior of some of these tumours. 
PAC represents second most common intraoral 
malignant salivary gland tumour. It typically 
presents as painless mass of variable duration (from 
few weeks to 40 years). The previously described 
cribriform adenocarcinoma of Tongue/minor salivary 
glands is now considered a feature within the PAC 
morphological spectrum.
Sclerosing polycystic adenosis is a new benign 
entity described. This is a rare lesion which most 
commonly involves parotid gland, and histologically 
resembles fibrocystic changes and sclerosing 
Dr Nasir Ud Din
Histopathology
adenosis of breast. Recurrence has been seen in 11% 
of cases that are incompletely excised or multifocal.
Tumours of the Oropharynx (Base of Tongue, 
Tonsils, Adenoids)
The changes for oropharyngeal lesions are dramatic 
and significant, largely due to the growing impact of 
high risk human papillomavirus (HPV).WHO has 
divided tumours of the oral cavity and oropharynx 
into separate chapters, classifies squamous cell 
carcinomas (SCC) of the oropharynx on the basis 
of HPV status, abandons the practice of histologic 
grading for oropharyngeal SCCs that are HPV 
positive, and recognizes small cell carcinoma of the 
oropharynx.
Separation of Oropharyngeal and Oral Cavity 
Tumours
Oral cavity proper is comprised of the lips, gingiva, 
retromolar trigone, hard palate, buccal mucosa, 
mobile tongue, and floor of the mouth. Oropharynx is 
comprised of the palatine tonsils, soft palate, tongue 
base (posterior to the circumvallate papillae), and 
posterior pharyngeal wall. Although the oral cavity 
and oropharynx form one continuous chamber lined 
by an uninterrupted stratified squamous epithelium 
and by historical convention have been lumped 
together under the blanket term “oral” or “oral 
cancer”, they are dissimilar in many important 
respects.
Most notable is the presence of tonsillar tissue (i.e. 
lingual and palatine tonsils) in the oropharynx, and 
its absence in the oral cavity. The highly specialized 
lymphoepithelium (i.e. reticulated epithelium) lining 
the tonsillar crypts provides a more permissive 
environment for HPV infection and HPV-driven 
tumourigenesis, resulting in much higher rates of 
HPV in SCCs of the oropharynx (OPSCC) than in 
SCCs of the oral cavity.
Recent analyses of cancer registry data show 
dramatic increases in incidence of oropharyngeal 
carcinomas during the past 15–20 years in several 
15
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parts of the world, even as the incidence of oral 
cavity carcinomas has remained constant or declined 
during the same period. 
These HPV-positive OPSCCs have unique 
demographic profiles, unique genetic features distinct 
from typical head and neck SCCs, distinct clinical 
& morphologic features, and have improved clinical 
outcomes.
HPV-related Small Cell Neuroendocrine Carcinoma
Some small cell carcinomas of the oropharynx 
represent HPV-positive squamous cell carcinomas, 
which have undergone small cell transformation. 
Like small cell carcinomas of the lung, these HPV-
positive small cell carcinomas of the oropharynx are 
associated with cigarette smoking, high grade cellular 
features, expression of neuroendocrine markers, and 
an aggressive clinical behavior including widespread 
dissemination and poor survival.
Tumours of the Nasal Cavity, Paranasal Sinuses 
and Skull Base
The sinonasal tract is the site of origin for a variety 
of neoplasms. Three new, relatively well-defined 
entities: NUT carcinoma, biphenotypic sinonasal 
sarcoma and seromucinous hamartoma are included. 
HPV-related carcinoma with adenoid cystic-like 
features is provisionally listed as a subtype of non-
keratinizing SCC.
NUT Carcinoma, a.k.a NUT midline carcinoma is a 
poorly differentiated carcinoma (often with evidence 
of squamous differentiation) defined by the presence 
of “nuclear protein in testis”(NUT) gene (NUTM1) 
rearrangement. It is a rare tumour with a median 
age of 21.9 years. Most cases (65 percent) occur 
in the nasal cavity & paranasal sinuses. Clinically, 
it presents as a rapidly growing mass manifested 
by nasal obstruction, pain & epistaxis. 50 percent 
present with lymph node involvement or distant 
metastatic disease. Prognosis is very poor. Median 
survival rate 9.8 months.
Biphenotypic Sinonasal Sarcoma is a low grade 
spindle cell sarcoma with distinctive histological, 
immunohistochemical, and molecular features. It is 
most frequently characterized by a recurrent PAX3-
MAML3 gene fusion. It predominantly affects 
females with mean age of 52 years (range 24-85 
years). The tumour typically involves multiple sites in 
the sinonasal tract, in particular superior aspect of the 
nasal cavity and ethmoid sinus. It is a slowly growing 
tumour with invasion of local structures. Nearly 50 
percent of patients experienced recurrence (as long as 
nine years after initial treatment). Neither metastatic 
disease nor death from disease has been reported.
Sinonasal Papillomas
Sinonasal (Schneiderian) papillomas are benign 
neoplasms that arise in the sinonasal tract. The lesion 
now regarded as sinonasal papilloma. A summary of the 
3 types of sinonasal papillomas are tabulated below. 
Conclusions
The new edition of the WHO Blue Book has arrived 
with great anticipation. Much has changed in 
Median age
Gender
Site
Risk factors
Lymph node metastasis
Postulated origin
Dysplasia
Morphology
Grading
Tumour stage at presentation
P16 immunostaining
Overall survival rate (3 years)
50-56 years
M=F
Base of Tongue, Palatine tonsil
Sexual behavior
Frequently cystic
Reticulated epithelium of invaginated crypts
Rare
Commonly non-keratinizing
Not applicable
Often higher (more nodal metastasis)
Positive
82%
60-70 years
M>F
Soft palate, pharyngeal wall
Smoking and alcohol use
Uncommonly cystic
Surface epithelium
Often present
Conventional SCC
Applicable
Often lower
Negative
57%
Table 1. Comparison of HPV-positive and HPV-negative oropharyngeal SCC
Characteristics HPV-Positive HPV-Negative
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H
PV
Sinonasal 
papilloma, 
Inverted type
Sinonasal 
papilloma, 
exophytic type
Sinonasal 
papilloma, 
oncoytic type
Lateral 
nasal wall 
& paranasal 
sinuses
Nasal 
septum
Lateral 
nasal wall 
& paranasal 
sinuses
5-15%
Close to 0%
4-17%
EGFR 
mutations
None 
known
KRAS 
mutations
Unclear 
association
Most caused 
by low-risk 
HPV-types
No 
association
-Thickened epithelium, scattered mucus 
cells or cysts, intraepithelial neutrophils, 
micro abscesses.
-Epithelium variably squamous, squamoid/
transitional, or ciliated columnar
- Prominent downward growth of rounded, 
elongated and anastomosing epithelial nests 
from surface epithelium
-Thickened epithelium, scattered mucus 
cells or cysts, intraepithelial neutrophils, 
micro abscesses.
-Epithelium usually squamous, sometimes 
squamoid/transitional.
-Broad, branching fronds of epithelium sur-
rounding fibrovascular cores
- +/- koilocytes
-Thickened epithelium, scattered mucus 
cells or cysts, intraepithelial neutrophils, 
micro abscesses.
-Both inverted and exophytic growth
-Epithelium pseudostratified columnar 
epithelium cells, with abundant granular 
cytoplasm & small hyperchromatic nuclei
head and neck pathology in the past 10–12 years, 
including a great deal in oropharyngeal tumours. 
With the alarming upsurge of HPV-positive OPSCC, 
the WHO has responded by creating a separate 
oropharynx chapter and separating OPSCCs on 
the basis of HPV status. Oropharyngeal small 
cell carcinomas can be HPV-positive and must be 
distinguished from SCC since they appear to be 
aggressive tumours, regardless of HPV status.
The terms pheochromocytoma and paraganglioma 
are often used interchangeably because 
morphologically and functionally these entities are 
the same. Paragangliomas that arise in the adrenal 
medulla are defined as pheochromocytomas, 
and those outside the adrenal gland are called 
Polymorphous adenocarcinoma will be the blanket term 
for tumours formerly designated as polymorphous low 
grade adenocarcinoma or cribriform adenocarcinoma of 
Tongue/minor salivary glands. Specific grade has been 
removed from the PAC.
Secretory carcinoma is introduced which has 
been previously called zymogen-poor acinic cell 
carcinoma or adenocarcinoma, NOS.
paragangliomas. Common symptoms of 
pheochromocytomas are episodic and sudden onset 
of severe headaches, sweating, and abdominal 
pain, high blood pressure that may be resistant to 
conventional medications, rapid heart rate, irritability 
and anxiety. These tumours produce excess 
Plasma Metanephrines in Diagnosis of 
Pheochromocytoma
Dr Syed Bilal Hashmi 
Chemical Pathology
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hormones called catecholamines, which are broken 
down to metanephrine. 
The Endocrine Society, European Society of 
Endocrinology, and American Association for 
Clinical Chemistry recommends that for patients 
who are being evaluated because of strong risk 
factors for a catecholamine-secreting tumour, 
such as those with known mutations for familial 
pheochromocytoma, the initial biochemical testing 
for pheochromocytomas and paragangliomas should 
include measurements of plasma free metanephrine 
or urinary fractionated metanephrine. Genetic 
testing in all patients is recommended. Computed 
tomography is suggested for initial imaging, but 
magnetic resonance is a better option in patients 
with metastatic disease or when radiation exposure 
must be limited. Diagnostic approach to evaluate a 
patient suspected of catecholamine secretion tumour 
is shown in figure 1.
The plasma free metanephrine test measures the 
amount of metanephrine and nor-metanephrine 
in the blood. Measurements of plasma free 
metanephrine are used for initial biochemical testing 
for diagnosis of pheochromocytoma and other 
tumours derived from neural crest cells. This test 
is somewhat more sensitive than 24-hour urinary 
fractionated metanephrine, likely because even 
small pheochromocytomas may continually leak 
metanephrine even if they are not actively secreting 
catecholamines. The test is also appropriate for 
individuals who are unable to perform an accurate 
24-hour urine collection, such as young children.  
All patients with positive test results should receive 
appropriate follow-up according to the extent of 
increased values and clinical presentation.
Note: There are some substances that can falsely 
increase the plasma metanephrine levels. So these 
should be avoided before getting tested for plasma 
metanephrine levels. These include:
l Tyrosine rich foods such as banana, cheese,   
 caffeine, citrus fruits or nuts.
l Medications such as MAO inhibitors, tricyclic  
 antidepressants, lidocaine and clonidine etc.
l Sleep medications, anxiolytics and    
 antihistamines.
l Alcohol and smoking.
 
Plasma
Metanephrines
>4 times URL
(Tumor 
probable)
3-4 times URL
(Tumor 
possible)
Normal
Normal
Tumor
unlikely
Results
elevated
Tumor
Possible
Clonidine
suppression
test
Elevated
Tumor
unlikely
Recent Plasma
Metanephrines
Figure 1: Diagnostic approach to evaluate a patient suspected of cat-
echolamine secretion tumour 
(Source: http://www.snp.com.au/media)
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Megaloblastic  Anemia
This is a group of anemias in which the erythroblasts 
in the bone marrow show a characteristic abnormality 
i.e maturation of nucleus being delayed relative to that 
of cytoplasm due to defective DNA synthesis.
Causes of Megaloblastic Anemia   
l Cobalamine( vitamin B12)
Cobalamin is synthesized solely by microorganisms. 
only source for humans is food of animal origin. Body 
stores are of the order of 2–3 mg and are sufficient for 
three–four years if supplies are completely cut off.  
l Folate
Most foods contain some folate. The highest 
concentrations are found in liver and yeast (>200 μg per 
100 g), spinach, other greens and nuts (>100 μg per 100 
g). Total body folate in the adult is about 10 mg. Stores 
are only sufficient for about 4 months in normal adults, 
so severe folate deficiency may develop rapidly.
l Pernicious Anaemia
Pernicious anaemia(PA) is defined as severe lack 
Dr Natasha Ali 
Hematology & Transfusion Medicine
of intrinsic factor (IF) due to gastric atrophy. The 
disease occurs more commonly than by chance in 
close relatives, in subjects or families with other 
organ-specific autoimmune diseases of the thyroid, 
adrenal or parathyroid, in those with premature 
greying, blue eyes and vitiligo, and in persons of 
blood group A. 
Clinical Feature of Megaloblastic Anemia
l Shortness of breath.
l Muscle weakness / Neuropathy.
l Abnormal paleness of the skin.
l Glossitis (swollen tongue)
l Loss of appetite/weight loss.
l Diarrhea.
l Nausea.
Laboratory Findings
CBC: Complete  blood count report macrocytic 
anemia with other cytopenias.  MCV is usually more 
than 96fl and can reach upto 140fl. 
Table 1. Causes of  cobalamin deficiency causing megaloblastic 
anaemia.
Table 2. Causes of  folate deficiency.
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and show open, fine, lacy primitive chromatin 
pattern but normal cytoplasmic hemoglobinization. 
Giant and abnormally shaped metamyelocytes are 
characteristic. 
Other investigations 
Serum vitamin B12 levels : low levels less  than 
B12<150ng/l .
Serum or erythrocyte folate levels: low levels of 
RBC folate confirm diagnosis.
Serum holotranscobalamine : early marker of B12 
deficiency <25pmol/L.
Methylmalonic acid (MMA) and homocysteine 
levels are raised.
Serum lactic dehydrogenase (LDH ) is raised.
Differential Diagnosis 
Conditions in which macrocytosis or 
hypersegmented neutrophils may occur in the 
absence of megaloblastic anaemia.
Peripheral film : Peripheral film shows typical 
oval macrocytes and hypersegmented neutrophils. 
Anisocytosis, poikilocytosis, polychromasia and 
Nucleated red blood cells seen. Erythrocytes may 
contain cabot rings. 
Bone marrow aspiration: The bone marrow is 
usually hypercellular and erythroblasts are large 
Figure 1: Peripheral film in a patient with megaloblastic anemia shows 
Oval macrocytes and  a  hypersegmented neutrophil in center.
Figure 2: Megaloblastic changes in the bone marrow in a patient with
severe megaloblastic anaemia. (a-c) Erythroblasts showing fine open 
stippled (primitive) appearance of the nuclear chromatin even in late 
cells (pale cytoplasm with some haemoglobin formation). (d) Abnormal 
giant metamyeiocytes and band forms.
Aplastic Anemia
Dr Sana Brohi
Haematology & Transfusion Medicines
Aplastic Anemia (AA) refers to pancytopenia in 
association with bone marrow hypoplasia/ aplasia, 
in absence of an abnormal infiltrate and with no 
increase in reticulin. In aplastic anemia, there must 
be at least two of the following: (i) hemoglobin 
below 100 g/l, (ii) platelet count below 50 X 109/L 
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Transfusion associated circulatory overload is a 
transfusion reaction in which pulmonary edema 
develops primarily due to volume excess or 
circulatory overload. According to Serious Hazards of 
Transfusion (SHOT) report 2016, it has been reported 
as one of the major causes of transfusion associated 
mortality. Reports of TACO increased steadily, from 
six to ninety six; deaths increased from one to twelve; 
and instances of major morbidity increased from three 
to thirty four from 2007 to 2017.
Transfusion Associated Circulatory Overload 
(Taco): A Severe But Preventable Transfusion 
Reaction
Dr Nazish Sana and Dr Mohammad Shariq Shaikh
Hematology and Transfusion Medicine
Figure 1: Bone marrow biopsy in aplastic anemia. There are virtually no 
hematopoietic cells, and the marrow space consists of fat and stroma.
Courtesy of Stanley L Schrier, MD.
and (iii) neutrophil count below 1.5 X 109/L. AA 
is a rare disorder (two to four per million per year) 
that affects men and women equally, and it is life-
threatening if untreated. AA is associated with loss 
of hematopoietic stem cells (HSCs) due to direct 
stem cell injury, viral suppression, autoimmune 
mechanisms, and inherited or acquired clonal/genetic 
abnormalities. Autoimmune damage to HSCs is an 
important contributor to most cases of AA in which 
no underlying cause is clearly identifiable (idiopathic 
AA). There are two types of AA: (i) Inherited 
aplastic anemia/bone marrow failure, (ii) Acquired 
aplastic anemia.
Laboratory Tests to Confirm Diagnosis
Full blood count (pancytopenia with 
reticulocytopenia), blood film examination, liver 
function tests, vitamin B12, and folate, virology, 
antinuclear antibody and dsDNA, bone marrow 
examination shows hypocellular/aplastic bone 
marrow biopsy, morphologically normal residual 
hematopoietic cells, and no infiltration with 
malignant cells or fibrosis; the marrow space is
composed mostly of fat cells and marrow stroma. 
Tests to detect an associated abnormal clone, 
Cytogenetic studies on bone marrow, CD55/59 
screen for paroxysmal nocturnal hemoglobinuria.
For purposes of risk stratification and selection of 
therapy, AA is classified according to the following 
criteria:
Severe AA — Diagnosis of severe aplastic anemia 
(SAA) requires both of the following criteria: (i) 
Bone marrow cellularity <25 percent, or 25 to 50 
percent with <30 percent residual hematopoietic 
cells. (ii) At least two of the following:
1. neutrophils <0.5 X 109 /L
2. platelets <20 X 109 /L
3. reticulocytes < 60 X 109 /L
Very severe AA — As for severe AA but neutrophils 
<0.2 X 109 /L.
Non-severe AA — Patients not fulfilling the criteria 
for severe or very severe AA.
Differential Diagnosis 
Other causes of pancytopenia, such as megaloblastic 
anemia, bone marrow infiltration (eg, myelofibrosis, 
various cancers), sequestration/redistribution (eg, 
hypersplenism), and certain myeloid malignancies 
(eg, myelodysplastic syndrome [MDS], acute 
myeloid leukemia [AML]),T-Large granular 
lymphocyte leukemia, paroxysmal nocturnal 
hemoglobinuria (PNH).
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Risk Factors
Risk factors include 
	 l Extremes of age (e.g., <3 years, >60 years)
	 l Low body weight
	 l Small stature
	 l Faster blood product infusion rate
	 l Pre-existing cardiac disease
	 l Pre-existing renal dysfunction 
	 l Pulmonary disease
	 l Hypoalbuminemia
	 l Positive fluid balance
Clinical Presentation
TACO presents as following sign/symptoms during 
or within six hours of completing a transfusion. 
	 l Acute respiratory distress, hypoxia, dyspnea, 
  or tachypnea
	 l Tachycardia
	 l Increased blood pressure
	 l Acute or worsening pulmonary edema
	 l Evidence of positive fluid balance e.g. wide 
  pulse pressure, and/or jugular venous 
  distension
Differential Diagnoses
	 l	 Transfusion-related acute lung injury 
(TRALI) is the top most differential 
diagnosis of TACO. Differentiating features 
include hypertension, raised jugular venous 
pressure, raised pulmonary arterial pressure 
to >18mmHg, positive fluid balance, raised 
brain natriuretic peptide levels (>1200pg/ml) 
and significant response to diuretic in TACO 
as compared to TRALI.
	 l Transfusion-associated dyspnea – Transfusion-
associated dyspnea is acute respiratory 
distress occurring within 24 hours of 
cessation of transfusion and do not meet the 
criteria for other transfusion reactions. 
	 l Anaphylactic transfusion reactions – 
Anaphylactic transfusion reactions occur 
when IgA-containing blood component 
transfused to IgA-deficient individual who 
has pre-formed antibodies to IgA. Unlike 
TACO, anaphylactic transfusion reactions 
occur at the initiation of the transfusion 
(before significant volume is infused) with 
no symptoms of circulatory overload.
Management
It includes immediately stopping the transfusion, 
fluid mobilization with diuretics, supplementary 
oxygen, and assisted ventilation if indicated.
Prevention
	 l Avoiding unnecessary transfusion.
	 l Limiting transfusion of RBCs to two units  
  per day in patients who are not actively   
  bleeding.
	 l Avoiding overly rapid transfusion rates and  
  reducing the volume of the transfusion.
	 l A transfusion rate of approximately 2.0 to  
  2.5 mL/kg per hour is reasonable 
	 l Patients with underlying risk factor for   
  TACO can be safely transfused at a rate of 
  1 mL/kg per hour and monitored more 
  closely during the transfusion for signs and 
  symptoms of TACO.
	 l Diuresis may be given before or during 
  transfusion in selected individuals e.g. 
  receiving chronic diuretic therapy, heart 
  failure, and with a history of TACO. 
AKUH Experience
A total of eight cases of TACO have been notified 
from January 2016 till September 2017. Significant 
underlying comorbidities like renal disease, heart 
disease, hypoalbuminemia, positive fluid balance 
and underlying pulmonary edema were identified 
as predisposing factors in all patients.  Five patients 
required prolonged hospital/special care unit stay 
whereas, 2 patients also required Bi-level Positive 
Airway Pressure (BiPAP) support.
Recommendations
According to Annual SHOT report 2016, whenever 
possible a formal pre-transfusion risk assessment for 
TACO should be performed as follows. 
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Conclusion
Transfusion associated circulatory overload is serious 
but preventable transfusion reaction. Appropriate 
pre-transfusion assessment in each patient is 
important in ensuring safe blood transfusion practice.
TACO Checklist
1
2
3
If ‘yes’ to any of these questions
Red Cell Transfusion
for Non-bleeding Patients
Does the patient have a diagnosis of ‘heart 
failure’ congestive cardiac failure (CCF), 
severe aortic stenosis, or moderate to severe 
left ventricular dysfunction?
Is the patient on a regular diuretic?
l	Review the need for transfusion (do the  
 benefits outweigh the risks)?
l	Can the transfusion be safely deferred  
 until the issue can be investigated, 
 treated or resolved?
l	Consider body weight closing for red  
 cells (especially if low body weight)
l	Transfuse one unit (red cells) and review
 symptoms of anaemia
l	Measure the fluid balance
l	Consider giving a prophylactic diuretic
l	Monitor the vital signs closely, 
 including oxygen saturation
Is the patient known to have pulmonary 
oedema?
Does the patient have respiratory symptoms
of undiagnosed cause?
Is the fluid balane clinically significantly 
positive?
Is the patient on concomitant fluids (or has 
been in the past 24 hours)?
Is there any peripheral oedema?
Does the patient have hypoalbuminaemia?
Does the patient have significant renal
impairment?
Due to the differences in adult and neonatal physiology, babies may have a different 
risk for TACO. Calculate the dose by weight and observe the notes above.
On April 26, 2018 in line with medical laboratories 
professionals’ week, an interactive session was 
organized by the section of Chemical Pathology, 
Department of Pathology and Laboratory Medicine, 
the Aga Khan University (AKU) in collaboration 
with Pakistan Society of Chemical Pathology 
(PSCP). This was a ‘first of its kind meeting’ 
conducted using a virtual platform ensuring 
Meeting Report: A Zoom Web Conferencing 
Session – Virtual Meet Up of Chemical 
Pathology Fraternity Across The Country and 
Discussion Regarding The Expected Changes 
in Upcoming Exam Patterns 
Dr Sibtain Ahmed
Chemical Pathology 
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maximum participation from Chemical Pathology 
training centers across the country. Chemical 
Pathology group from Karachi gathered at AKU with 
participation from Sindh Institute of Urology and 
Transplant, PNS Shifa, Liaquat National Hospital, 
Ziauddin University Hospital, Dow University 
of Health Sciences and Indus Hospital. A virtual 
podium was utilized for the meeting based on ZOOM 
that enabled participation from various centers 
across the country specifically SMDC Lahore, AFIP 
Rawalpindi, CMH Quetta, QAMC Bahawalpur, 
SZMC Rahim Yar Khan and RMIT Peshawar. During 
the two hour session, almost all the recognized 
centers across Pakistan (Karachi, Rawalpindi, 
Lahore, Peshawar, Quetta, Bahawalpur and Rahim 
Yar Khan) were on board.
The ideology behind this activity was to develop 
connections of Chemical Pathology trainees from 
across Pakistan with supervisors and discuss the 
expected changes in upcoming exam patterns 
including intermediate module (IMM) and FCPS part 
2. Maximum time was spent in discussions on the 
overview of curriculum and assessment in IMM.
The activity was officially called on by a welcome 
note by Prof Dr. Imran Siddiqui, one of the pioneers 
of Chemical Pathology at AKU. He emphasized on 
Picture 2: Participants from other cities of Pakistan connected via Zoom.
Picture 1: Participants From Karachi gathered at Aga Khan University.
the significance of such collaborative activities and 
its value for the young blood. His talk was followed 
by an introduction from all the attendees. The next 
talk was by Prof Dr. Aamir Ijaz who shed light on 
the overview of curriculum and assessment in IMM 
of Pathology. His session was of utmost importance 
for all the trainees and as expected was followed 
by a variety of questions. The next dialogue was by 
Dr Adnan Mustafa Zuberi, he presented an update 
of expected changes in FCPS-II examination of 
Chemical Pathology. This was a very informative 
presentation for the trainees especially those 
approaching the upcoming examination and was 
further supported by key tips from Dr. Imran Siddiqui 
and Dr. Aamir Ijaz.
Dedicated assessment and curriculum allied sessions 
were followed by a discussion by Prof Dr. Asma 
Shaukat who gave vital tips and instructions for trainees 
to successfully ace the residency period and complete 
their requirements to be eligible for the exit exam 
in due course of time. Subsequently Brig Dr. Brig. 
Muhammad Aamir delivered a talk on opportunities 
for trainees in upcoming cities of Pakistan. He 
discussed regarding the constraints faced by trainees 
in far flung areas and how to overcome them with the 
help of bigger established centers. The last talk of the 
meeting was by section head of Chemical Pathology 
AKU, Dr. Aysha Habib Khan who suggested young 
Chemical Pathologists to explore broader horizons in 
future specially focusing on metabolic medicine as 
subspecialty training. Lots of questions were raised in 
the two hours networking session by the trainees and 
were responded by the panelists.  
The event came to conclusion with a vote of thanks 
from Dr. Aysha Habib Khan. She appreciated event 
organizers Dr. Hafsa Majid and Dr. Sibtain Ahmed 
for this initiative and encouraged the participants 
to utilize such platform in future as well for the 
maximum benefits of our fraternity.
Picture 3: Chemical Pathology faculty answering queries of participants 
during the zoom session
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